A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Recruiting · NCT06978920 · Interventional (participants receive a specific treatment) · Lead sponsor: Nuwacell Biotechnologies Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
Allogeneic dopaminergic neural precursor cell(NCR201)
What this trial is about
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Who can take part
Age range
40 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Ages between 40 and 75 years;
- Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;
- Disease history over 5 years;
- Stable dose of dopamine treatment;
- Able to undergo PET/CT/MRI detection;
Exclusion criteria
- Patients who have previously undergone brain surgery;
- Past use of stem cell therapy or participation in stem cell clinical research;
- Cognitive impairment;
- History of mental disorders;
- Patients with other serious systemic diseases;
- Past or current metastatic malignant tumors.
Where it is running
1 location listed.
- The First Affiliated Hospital of USTC - Hefei, Anhui, China